AC
TPTX

Athanor Capital’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Athanor Capital’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,394
Closed -$226K – 952
2021
Q1 		$226K Sell
2,394
-4,222
-64% -$502K 0.01% 669
2020
Q4 		$806K Sell
6,616
-1,905
-22% -$209K 0.02% 358
2020
Q3 		$744K Sell
8,521
-5,625
-40% -$392K 0.03% 277
2020
Q2 		$914K Buy
+14,146
New +$816K 0.05% 208
2020
Q1 		– Sell
-18,600
Closed -$1.16M – 398
2019
Q4 		$1.16M Sell
18,600
-5,200
-22% -$247K 0.05% 142
2019
Q3 		$895K Buy
23,800
+10,600
+80% +$461K 0.06% 128
2019
Q2 		$537K Buy
+13,200
New +$471K 0.07% 95

Other funds holding TPTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Athanor Capital's TPTX Position: Q2 2021 in Review

Athanor Capital sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q2 2021, closing a stake of 2,394 shares — an estimated $226K sold.

Athanor Capital first reported a position in TPTX in Q2 2019 and held it in 7 quarters. The position peaked at $1.16M in Q4 2019. 190 funds tracked by Wall St. Rank hold TPTX as of Q2 2021.

  • Athanor Capital reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Athanor Capital sold 2,394 Turning Point Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $226K.
  • Athanor Capital first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2019 and held it in 7 quarters.
  • Athanor Capital's Turning Point Therapeutics, Inc. Common Stock position peaked at $1.16M in Q4 2019.
  • 190 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Athanor Capital's 13F filing for Q2 2021, filed 16 Aug 2021.